Regadenoson

證據等級: L5

預測適應症: 4 個

# Regadenoson: Pharmacological Stress Agent — Repurposing Evaluation Incomplete

## One-Sentence Summary

Regadenoson (Lexiscan®) is a selective adenosine A2A receptor agonist approved in the
United States as a pharmacological stress agent for radionuclide myocardial perfusion
imaging (MPI).
This Evidence Pack **contains no TxGNN repurposing predictions** for Regadenoson, and
the drug is **not currently marketed in Taiwan**.
Evaluation cannot proceed to full repurposing analysis until the critical data gaps
documented below are resolved.

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Pharmacological stress agent for myocardial perfusion imaging (US; not approved in Taiwan) |
| Predicted New Indication | No prediction available |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 — model prediction absent; no supporting studies in pack |
| Taiwan Market Status | ✗ Not marketed (0 authorizations) |
| Number of Authorizations | 0 |
| Recommended Decision | **Hold** |

## Safety Considerations

Please refer to the package insert for safety information.

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
This Evidence Pack contains no TxGNN repurposing predictions for Regadenoson, and all
drug-level safety data (warnings, contraindications, drug interactions) are absent,
making a repurposing evaluation impossible at this stage.

**To proceed, the following is needed:**

- **TxGNN prediction output** — rerun the TxGNN pipeline with Regadenoson as input to
  obtain candidate repurposing indications and confidence scores
- **Mechanism of action (MOA)** — retrieve from DrugBank API (DB06213); severity
  flagged as High in this pack
- **Taiwan package insert safety data** — download and parse the TFDA package insert
  PDF to extract warnings and contraindications (flagged as Blocking)
- **Drug–drug interaction profile** — DDI query returned `not_found`; a targeted
  literature search or DrugBank DDI lookup is recommended
- **Original indication confirmation** — `original_indications` field is empty;
  confirm approved indication(s) from the authoritative label (FDA: MPI stress testing)
  and populate the Evidence Pack before resubmission

報告說明：

此 Evidence Pack（TW-DB06213-multi v4）存在兩個關鍵缺口：

predicted_indications 為空陣列 — TxGNN 尚未對 Regadenoson 產生預測，標準「From X to Y」格式無法套用。
所有安全性欄位均為 [Data Gap] — TFDA 警語/禁忌（DG001，Blocking）尚未填入。

依照報告規則「有資料才列章節」，已省略：臨床試驗證據、文獻證據、台灣市場資訊（0 張許可證）、細胞毒性（非抗腫瘤藥物）等章節。建議補齊上述缺口後重新提交 Evidence Pack，再執行正式評估。

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.

Field	Value
`predicted_indications`	Empty — no TxGNN output
`original_indications`	Empty
`original_moa`	[Data Gap]
`taiwan_regulatory.market_status`	未上市 (0 licenses)
`safety`	All [Data Gap]

Regadenoson

目錄

Disclaimer